XNCR stock forecast, quote, news & analysis
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases... Show more
Xencor (XNCR) Stock Analysis: Pipeline Momentum Builds Ahead of XmAb819 Kidney Cancer Data
Key Takeaways
- Xencor shares have been essentially flat over the trailing 30 days, moving roughly 0.4% lower from about $25.03 to near $24.94.
- The stock has climbed roughly 50% year-to-date, driven by momentum in its oncology pipeline rather than near-term earnings.
- The key near-term catalyst is Phase 1 data for XmAb819, its ENPP3 x CD3 bispecific antibody in advanced clear cell renal cell carcinoma (ccRCC).
- Xencor remains a clinical-stage, unprofitable company whose valuation hinges on clinical milestones and partner collaborations.
Current Market Snapshot
Xencor (XNCR) has traded in a relatively tight range in recent weeks, with shares hovering near the $24 mark after pulling back from a 52-week high above $30. Over the trailing 30 days, the stock has been roughly flat, consolidating after a strong run higher earlier in 2026. The company carries a market capitalization of approximately $1.7 billion and generates revenue primarily through licensing, milestones, and royalties tied to its partnered programs rather than direct product sales.
Investor attention is centered on Xencor's next clinical data readouts, particularly around XmAb819, which has reframed how the market weighs near-term catalysts against the company's still-early commercial profile. Because Xencor is not yet profitable, traditional valuation metrics such as price-to-earnings are less meaningful, and sentiment tends to swing with pipeline updates and regulatory developments.
Xencor (XNCR) Business Overview and Competitive Position
Xencor, Inc. is a clinical-stage biopharmaceutical company headquartered in Pasadena, California, that develops engineered antibodies for the treatment of cancer and autoimmune diseases. Its core asset is the XmAb antibody engineering platform, which enables targeted modifications to protein structure to create new mechanisms of therapeutic action, including bispecific antibodies and Fc domains engineered for enhanced potency, safety, and half-life.
The company has more than 20 candidates engineered with XmAb technology in clinical development, and several XmAb-based medicines are marketed by partners. Its wholly owned pipeline includes XmAb942, XmAb819, XmAb808, and XmAb541, while partner-advanced programs include Xaluritamig with Amgen (AMGN), JNJ-9401 and JNJ-1493 with Johnson & Johnson (JNJ), and ASP2138 with Astellas. This partner-heavy model provides non-dilutive revenue while allowing Xencor to advance select wholly owned assets independently.
Recent Developments Driving XNCR
The dominant development for Xencor has been its XmAb819 program, a first-in-class ENPP3 x CD3 T-cell engaging bispecific antibody being developed for advanced clear cell renal cell carcinoma and other ENPP3-positive tumors. The company presented Phase 1 results in an oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid and hosted a webcast to discuss the data, while flagging plans to initiate a registration-enabling study of XmAb819 monotherapy in advanced ccRCC in 2027.
Alongside the lead oncology asset, Xencor has advanced its autoimmune pipeline, with plamotamab (CD20 x CD3) and XmAb657 (CD19 x CD3) studies progressing and updates expected in the second half of 2026. Separately, the company reached a $105 million settlement with Alexion, a unit of AstraZeneca (AZN), which supported its financial runway ahead of a U.S. Food and Drug Administration decision on obexelimab for IgG4-related disease.
On the analyst front, Raymond James added Xencor to its healthcare focus list in October 2026, citing anticipation around the ESMO data set and the potential for near-term upside if XmAb819 results support a clear path to pivotal development. The average analyst price target has also ticked higher in recent months, reflecting improved outlooks on the oncology programs.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page highlights a curated selection of top-performing artificial intelligence trading bots. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the most relevant and best-performing strategies appear in this focused section. These bots vary widely in trading strategy, timeframe, and performance metrics, allowing users to explore approaches that align with different risk tolerances and market conditions. Whether you follow established names or emerging biotech movers, reviewing the Trending AI Robots section can help identify automated strategies currently gaining traction.
2026 Outlook and What Investors Should Watch
Looking ahead, Xencor's trajectory will likely be shaped by the durability and quality of its XmAb819 data and its ability to transition the program into a registration-enabling study. Investors should monitor the recommended Phase 3 dose selection, expansion-cohort results, and any updates on subcutaneous administration and additional ENPP3-positive tumor sub-studies.
Beyond oncology, the company's autoimmune programs, including plamotamab and XmAb657, are expected to provide progress updates, while the obexelimab regulatory decision and associated milestone and royalty potential remain important financial catalysts. Macroeconomic conditions, biotech sector sentiment, and competitive dynamics in the T-cell engager and autoimmune spaces will also influence performance. As with any clinical-stage biotech, trial outcomes, regulatory decisions, and financing activity carry meaningful risk, and investors should weigh pipeline promise against the company's ongoing operating losses.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
XNCR sees its Stochastic Oscillator ascending out of oversold territory
On October 20, 2026, the Stochastic Oscillator for XNCR moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 51 instances where the indicator left the oversold zone. In 41 of the 51 cases the stock moved higher in the following days. This puts the odds of a move higher at over 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XNCR as a result. In 58 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for XNCR just turned positive on October 21, 2026. Looking at past instances where XNCR's MACD turned positive, the stock continued to rise in 32 of 48 cases over the following month. The odds of a continued upward trend are 67%.
Following a +8.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where XNCR advanced for three days, in 188 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
XNCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
XNCR moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XNCR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for XNCR entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.717) is normal, around the industry mean (2.988). P/E Ratio (-11.648) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.740) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (16.949) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics to treat autoimmune and allergic diseases, cancer and other conditions
Industry Biotechnology